The Impact of Oxytocin Vaginal Gel on Sexual Function in Postmenopausal Women: A Randomized Controlled Trial

Abedi, Parvin; Zohrabi, Ilnaz; Ansari, Somayeh; Maraghi, Elham; Maram, Nader Shakiba; Houshmand, Gholamreza

doi:10.1080/0092623x.2020.1738606

Cited by 11 publications

(21 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The five included studies 23–27 were double-blinded, randomized, placebo-controlled trials. Three of them were multicentre and had been conducted in Sweden 23 , 24 one trial in Egypt 26 and other in Iran.…”

Section: Resultsmentioning

confidence: 99%

“…The PRISMA guidelines for reporting systematic reviews and meta-analyses of randomized controlled trials (RCTs) were followed by the authors. 27…”

Section: Methodsmentioning

confidence: 99%

“…29 The assessment of different sources of bias showed that all except one trial (unclear allocation concealment) 27 were low risk in terms of selection bias (related to sequence generation and allocation concealment), performance bias (related to blinding the participants and research collaborators) and detection bias (related to blinding the outcome assessors) as well. 23–26 A low risk of attrition bias (related to withdrawals or incomplete follow-ups) 23–27 and high-risk reporting bias (related to incomplete outcome data and selective reporting of outcomes) was considered for three studies. 23 , 24 , 27 Only one RCT had an unclear risk of detection bias because it did not provide sufficient information about assessor blinding.…”

Section: Methodsmentioning

confidence: 99%

“…23–26 A low risk of attrition bias (related to withdrawals or incomplete follow-ups) 23–27 and high-risk reporting bias (related to incomplete outcome data and selective reporting of outcomes) was considered for three studies. 23 , 24 , 27 Only one RCT had an unclear risk of detection bias because it did not provide sufficient information about assessor blinding. 27 Risk of bias graph and risk of bias summery are shown in Figures 1 and 2.…”

Section: Methodsmentioning

confidence: 99%

“…23 , 24 , 27 Only one RCT had an unclear risk of detection bias because it did not provide sufficient information about assessor blinding. 27 Risk of bias graph and risk of bias summery are shown in Figures 1 and 2.…”

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

The efficacy and safety of intravaginal oxytocin on vaginal atrophy: A systematic review

Ghorbani

Mirghafourvand

2020

Post Reprod Health

View full text Add to dashboard Cite

Genitourinary syndrome of menopause is a major issue in menopausal health. Because unlike vasomotor symptoms, it has a progressive trend. In this regard we conducted a systematic review to evaluate the efficacy of intravaginal oxytocin on postmenopausal vaginal atrophy. A search was performed for published studies in Cochrane Library, MEDLINE, Web of Science, Embase, Scopus, ProQuest, Google Scholar and Persian databases without time and language limitations. Only randomized controlled trials that compared intravaginal oxytocin with placebos were included. The outcome measures were objective and subjective assessed symptoms of vaginal atrophy. Statistical heterogeneity was evaluated using the I2. The standardized mean differences were pooled the fixed effects model. Of the five included studies, four studies meta-analysed. The meta-analysis in terms of the cytological analysis (standardized mean difference: 35.13, 95% confidence interval: 32.59–37.67, n = 218, I2 = 96%) was statistically significant. In terms of histological assessments (standardized mean difference: −0.38, 95% confidence interval: −0.94 to 0.17, n = 38, I2 = 0%) and endometrial thickness (standardized mean difference: 0.05, 95% confidence interval: −0.20 to −0.31, n = 95, I2 = 0%), there were no statistically significant differences between the groups. Three studies reported a statistically significant improvement in the subjective symptoms; however, we were unable to perform a meta-analysis. Four of the included studies assessed side effects, but only two studies reported them. Oxytocin as a nonestrogenic compound can be a suitable alternative for the treatment of vaginal atrophy, especially in women with contraindications for using estrogenic compounds. Further good quality clinical trials with long-term follow-ups are recommended to demonstrate the effects of intravaginal gel in the treatment of vaginal atrophy.

show abstract